The association between CDK4/6i with anti-hormonal therapies certainly deserves to be mentioned for its promising results in gynecological malignancy, particularly in hormone receptor positive endometrial and ovarian cancers where endocrine agents are generally used alone in later treatment lines. The gene discussed is CDK4; the disease is ovarian carcinoma.